Synopsis :

Sun Pharma shares are in focus post Q2, where growth remained steady with 9% revenue rise and 3% PAT YoY, while sequential profit improved meaningfully. Brokerages remain cautious with muted PAT visibility ahead, despite strong India and EM traction and the US innovative mix shift.

This company is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs) is now in the focus after reporting Q2 results with net profit increasing by 3% year on year.

With market capitalization of Rs. 4,05,488 cr, the shares of Sun Pharmaceutical Industries Ltd are currently trading at Rs. 1,685 per share, increasing 2% in today’s market session making a high of Rs. 1,720.45, from its previous close

See Full Page